11/7
11:30 pm
stro
Sutro Biopharma (NASDAQ:STRO) had its "neutral" rating reaffirmed by analysts at Wedbush. They now have a $2.00 price target on the stock.
Low
Report
Sutro Biopharma (NASDAQ:STRO) had its "neutral" rating reaffirmed by analysts at Wedbush. They now have a $2.00 price target on the stock.
11/7
11:30 pm
stro
Sutro Biopharma (NASDAQ:STRO) had its "neutral" rating reaffirmed by analysts at Wedbush. They now have a $2.00 price target on the stock.
Low
Report
Sutro Biopharma (NASDAQ:STRO) had its "neutral" rating reaffirmed by analysts at Wedbush. They now have a $2.00 price target on the stock.